| __timestamp | Blueprint Medicines Corporation | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 20140000 |
| Thursday, January 1, 2015 | 14456000 | 37173000 |
| Friday, January 1, 2016 | 19218000 | 48616000 |
| Sunday, January 1, 2017 | 27986000 | 108488000 |
| Monday, January 1, 2018 | 47928000 | 244622000 |
| Tuesday, January 1, 2019 | 96388000 | 287000000 |
| Wednesday, January 1, 2020 | 157743000 | 354000000 |
| Friday, January 1, 2021 | 195293000 | 186000000 |
| Saturday, January 1, 2022 | 237374000 | 151000000 |
| Sunday, January 1, 2023 | 295141000 | 232600000 |
| Monday, January 1, 2024 | 359272000 | 267474000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Blueprint Medicines Corporation and Ionis Pharmaceuticals, Inc. have been navigating this landscape since 2014. Over the years, Blueprint Medicines has shown a steady increase in SG&A expenses, peaking at approximately $295 million in 2023. In contrast, Ionis Pharmaceuticals experienced a more volatile trend, with expenses reaching their zenith in 2020 at around $354 million before declining to $233 million in 2023.
From 2014 to 2023, Blueprint Medicines' SG&A expenses grew by nearly 3,600%, while Ionis Pharmaceuticals saw a 1,100% increase. This suggests Blueprint's aggressive expansion strategy, whereas Ionis appears to be optimizing costs post-2020. Understanding these trends offers valuable insights into each company's strategic priorities and financial management.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Ionis Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and Perrigo Company plc
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc. Trends and Insights